Loading clinical trials...
Loading clinical trials...
A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe COVID-19
Conditions
Interventions
Remdesivir
Standard of Care
Locations
183
United States
Kaiser Permanente Los Angeles Medical Center, 3340 E. La Palma Avenue
Anaheim, California, United States
Alta Bates Summit Medical Center
Berkeley, California, United States
Mills-Peninsula Medical Center
Burlingame, California, United States
Eden Medical Center
Castro Valley, California, United States
Kaiser Permanente Los Angeles Medical Center, 9333 Imperial Highway
Downey, California, United States
Kaiser Permanente Los Angeles Medical Center, 9961 Sierra Ave
Fontana, California, United States
Start Date
March 6, 2020
Primary Completion Date
April 9, 2020
Completion Date
June 30, 2020
Last Updated
December 31, 2020
NCT06631287
NCT05101213
NCT04565665
NCT06871293
NCT04978571
NCT07221162
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions